17388-39-5

Basic information

• Product Name: Swertiamarine
• Synonyms: (4ar-(4a-alpha,5-beta,6-alpha))-ranosyloxy)-4a-hydroxy;1h,3h-pyrano(3,4-c)pyran-1-one,4,4a,5,6-tetrahydro-5-ethenyl-6-(beta-d-glucopy;1H,3H-Pyrano[3,4-c]pyran-1-one,4,4.alpha.,5,6-tetrahydro-5-ethenyl-6-(.beta.-D-glucopyranosyloxy)-4.alpha.-hydroxy-,[4ar-(4.alpha.-.alpha.,5-.beta.,D-.alpha.)]-;3H-Pyrano[3,4-c]pyran-1-one,4,4.alpha.,5,6-tetrahydro-5-ethenyl-6-(.beta.-D-glucopyranosyloxy)-4.1H;4-c)pyran-1-one,4,4a,5,6-tetrahydro-5-ethenyl-6-(beta-d-glucopyranosyloxy)-4a-hydroxy-3h-pyrano(1;Swertiamarin(6CI,7CI,8CI);Swertiamarine;Swertiamaroside
• CAS NO: 17388-39-5
• Molecular Formula: C₁₆H₂₂O₁₀
• Molecular Weight: 374.34
• Product Categories: Sugars, Carbohydrates & Glucosides;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;Inhibitors
• Mol File: 17388-39-5.mol
• Article Data: 1

Chemical Properties

• Melting Point: 113-114°
• Boiling Point: 649.3 °C at 760 mmHg
• Flash Point: 237.7 °C
• Appearance: /
• Density: 1.57 g/cm³
• Vapor Pressure: 1.32E-19mmHg at 25°C
• Refractive Index: 1.625
• Storage Temp.: ?20°C
• PKA: 11.56±0.60(Predicted)
• Merck: 14,9010
• BRN: 55278
• CAS DataBase Reference: Swertiamarine(CAS DataBase Reference)
• NIST Chemistry Reference: Swertiamarine(17388-39-5)
• EPA Substance Registry System: Swertiamarine(17388-39-5)

Safety Data

• Safety Statements: 24/25
• WGK Germany: 3
• RTECS: UQ1366700
• Hazardous Substances Data: 17388-39-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Applications:
Swertiamarine is used as a therapeutic agent for the treatment of type 1 and type 2 diabetes. It helps in sensitizing the cells to hypolipidemic conditions and insulin, thereby aiding in the regulation of blood sugar levels and improving overall glucose metabolism.
Used in Drug Delivery Systems:
In the pharmaceutical industry, Swertiamarine is also utilized in the development of novel drug delivery systems to enhance its bioavailability, targeting efficiency, and therapeutic outcomes. These systems may include encapsulation in nanoparticles, liposomes, or other carriers to improve the compound's stability, solubility, and targeted delivery to specific cells or tissues.

InChI:InChI=1/C16H22O10/c1-2-7-14(24-6-8-13(21)23-4-3-16(7,8)22)26-15-12(20)11(19)10(18)9(5-17)25-15/h2,6-7,9-12,14-15,17-20,22H,1,3-5H2/t7-,9+,10+,11-,12+,14-,15-,16+/m0/s1

Downstream Products

• 50276-98-7 5-formyl-2,3-dihydroisocoumarin 
• 90921-13-4 1-oxo-isochroman-5-carboxylic acid 

Relevant articles and documents

Rigenolide A, a new secoiridoid glucoside with a cyclobutane skeleton, and three new acylated secoiridoid glucosides from Gentiana rigescens Franch

Rigenolide A (1), a new secoiridoid glucoside with a cyclobutane skeleton and three new acylated secoiridoid glucosides, 2′-(2,3-dihydroxybenzoyl)- gentiopicroside (2), 2′-(2,3-dihydroxybenzoyl)-swertiamarin (3), 3′-(2,3-dihydroxybenzoyl)-sweroside (4), along with two noriridoids (7 and 8) and two known secoiridoid glucosides (5 and 6), were isolated from Gentiana rigescens Franch. The structures of new compounds were elucidated by extensive spectroscopic analyses. The isolated compounds were evaluated for DPPH free-radical scavenging activity.